Inactive Instrument

Other languages BioTime, Inc. Nyse

Equities

US09066L1052

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit	05-06
Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors	04-29
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	03-11
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury	02-13
Lineage Cell Therapeutics Launches $14 Million Registered Direct Offering	02-06
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury	12-18
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Lineage Cell Therapeutics, Inc. Announces to Present Rg6501 Phase 1/2A Results to Be Featured At Eyecelerator At 2023 American Academy of Ophthalmology	24/10/23
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration	15/10/23
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501	05/10/23
EARNINGS: R&Q Insurance loss swells, Jade Road still selling assets	29/09/23
Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501	13/09/23
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Lineage Cell Therapeutics, Cancer Research UK Report 'Encouraging' Results in Lung Cancer Trial	24/07/23
Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer	24/07/23
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Lineage Cell Therapeutics, Inc. Announces Results from Imaging Analyses of Structural Changes and Visual Data from a Phase 1/2a Clinical Study of RG6501	27/04/23
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23
Lineage Enters into Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications	22/02/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioTime, Inc. Nyse

Equities

US09066L1052

Other languages

Filters